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Purpose: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause
of blindness. Even while central visual acuity remains relatively well preserved, GA often causes considerable
compromise of visual function and quality of life. No treatment currently exists. We evaluated the safety and
efficacy of pegcetacoplan, a complement C3 inhibitor, for treatment of GA.
Design: Prospective, multicenter, randomized, sham-controlled phase 2 study.
Participants: Two hundred forty-six patients with GA.
Methods: Patients with GA were assigned randomly in a 2:2:1:1 ratio to receive intravitreal injections of 15
mg pegcetacoplan monthly or every other month (EOM) or sham intravitreal injections monthly or EOM for 12
months with follow-up at months 15 and 18. Area and growth of GA were measured using fundus auto-
fluorescence imaging.
Main Outcome Measures: The primary efficacy end point was mean change in square root GA lesion area
from baseline to month 12. Secondary outcome measures included mean change from baseline in GA lesion area
without the square root transformation, distance of GA lesion from the fovea, best-corrected visual acuity (BCVA),
low-luminance BCVA, and low-luminance visual acuity deficit. The primary safety end point was the number and
severity of treatment-emergent adverse events.
Results: In patients receiving pegcetacoplan monthly or EOM, the GA growth rate was reduced by 29%
(95% confidence interval [CI], 9e49; P ¼ 0.008) and 20% (95% CI, 0e40; P ¼ 0.067) compared with the sham
treatment group. Post hoc analysis showed that the effect was greater in the second 6 months of treatment, with
observed reductions of 45% (P ¼ 0.0004) and 33% (P ¼ 0.009) for pegcetacoplan monthly and EOM, respec-
tively. Two cases of culture-positive endophthalmitis and 1 case of culture-negative endophthalmitis occurred in
the pegcetacoplan monthly group. New-onset investigator-determined exudative AMD was reported more
frequently in pegcetacoplan-treated eyes (18/86 eyes [20.9%] and 7/79 eyes [8.9%] in monthly and EOM groups,
respectively) than in sham-treated eyes (1/81 eyes [1.2%]).
Conclusions: Local C3 inhibition with pegcetacoplan resulted in statistically significant reductions in the
growth of GA compared with sham treatment. Phase 3 studies will define the efficacy and safety profile
further. Ophthalmology 2020;127:186-195 ª 2019 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.
See Commentary on page 196.Geographic atrophy (GA) is a late stage of age-related
macular degeneration (AMD), a chronic disease of the
retina and a major cause of irreversible blindness.1 In the
United States, GA affects nearly 1 million people and
accounts for approximately one quarter of cases of legal186 ª 2019 by the American Academy of Ophthalmology
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culty with reading and driving and significantly affects
quality of life.2,4 The disease is characterized by loss of
retinal pigment epithelium, photoreceptors, and underlying
choriocapillaris.5 Areas of atrophy enlarge and mayvier Inc.
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Liao et al  Pegcetacoplan for GAcoalesce, leading to irreversible loss of central vision. Even
while visual acuity remains relatively well preserved, GA
often causes considerable compromise of visual function
as a result of parafoveal scotomas and foveal function
abnormalities.6 Approximately 50% of patients with
unilateral GA demonstrate bilateral GA within 7 years of
diagnosis.7 Geographic atrophy also is common in patients
with neovascular AMD, the other form of late AMD.8,9
Although neovascular AMD usually can be treated effec-
tively with vascular endothelial growth factor (VEGF) in-
hibitors, patients frequently demonstrate GA within 5 years
of starting therapy.10 There are no approved treatments
for GA.
The complement system plays critical roles in both innate
and adaptive immunity, contributing to immune surveillance,
inflammation, and homeostasis via 3 different activation
pathways (classical, alternative, and lectin) and numerous
effector molecules.11 Its diverse functions include
recruitment and activation of immune cells, opsonization of
pathogens to target them for phagocytosis, and direct
destruction of pathogens by the membrane attack complex.
Under normal conditions, mammalian complement is
tightly regulated to avoid damage to host cells.
Dysregulation of the complement system seems to be a
major contributor to the pathogenesis of AMD. Genetic
variants of complement C3dthe central component of all 3
complement activation pathwaysdand variants of CFH,
CFI, and CFBdfactors that affect C3 activation or
degradation of its active fragmentsdare associated strongly
with increased risk of both the exudative and atrophic forms
of AMD.12,13 Complement activation products have been
identified at elevated levels in plasma of AMD patients and
locally deposited in ocular tissues, most notably in
drusen.14e17 Moreover, oxidative stress has been linked to
AMD through formation of neoepitopes that bind to autoan-
tibodies capable of activating complement.18e20
Despite considerable investigation,19,21e25 understanding
of how different complement activation pathways and ef-
fectors contribute to development and progression of AMD
remains incomplete. Given the potential involvement of
multiple pathways and effectors, C3 is an attractive target in
AMD because it is the point of convergence for all 3 acti-
vation pathways and is upstream of all major effectors. The
Filly phase 2 trial (ClinicalTrials.gov identifier
NCT02503332) was conducted to evaluate the safety,
tolerability, and efficacy of intravitreally administered peg-
cetacoplan, a pegylated complement C3 inhibitor peptide,
given monthly or every other month (EOM) to patients with
GA secondary to AMD.Methods
Study Design
The 18-month prospective, multicenter, randomized, sham-
controlled phase 2 study enrolled patients at 46 sites in the
United States (New England Institutional Review Board, Univer-
sity of Miami, Mayo Clinic, Institutional Review Board of the
Cleveland Clinic Foundation, Duke University Health System
Institutional Review Board, and Research Compliance Office,Stanford University), Australia (Bellberry Ltd), and New Zealand
(Northern A Health and Disability Ethics Committee, Health and
Disability Ethics Committees, and Ministry of Health). The study
was performed in accordance with the tenets of the Declaration of
Helsinki, International Conference on Harmonization Good Clin-
ical Practice guidelines, and all applicable regulations. Institutional
review board or ethics committee approval was obtained at each
site. All patients provided written informed consent.
Eligible patients were randomized in a 2:2:1:1 ratio to receive
15 mg pegcetacoplan monthly, 15 mg pegcetacoplan EOM, sham
injection monthly, or sham injection EOM for 12 months (Fig 1).
Randomization was performed using a web-based system, and
the randomization schedule was blocked to ensure balanced
treatment allocations within sites. Pegcetacoplan was adminis-
tered by intravitreal injection in a 100-ml volume using a thin-
walled needle of either 27 gauge or 29 gauge. Patients returned
to the study site to be assessed for acute safety 7 days after the
first injection. Thereafter, patients received additional pegceta-
coplan (or sham) injections monthly or EOM through month 12
and returned at months 15 and 18 for safety and efficacy follow-
up. Patients who discontinued treatment could remain in the
study and receive scheduled study procedures (except pegceta-
coplan or sham injection). Patients, study personnel responsible
for performing imaging and visual acuity assessments, and
reading center personnel were masked to treatment assignment.
The sponsor, physicians administering injections and assessing
adverse events, and other study personnel not involved in effi-
cacy assessments were not masked.
The sponsor, Apellis Pharmaceuticals, was responsible for study
design and data analysis, with input from investigators and other
retinal specialists. See the Appendix (available at
www.aaojournal.org) for further details. The trial is registered with
ClinicalTrials.gov (identifier, NCT02503332). Apellis provided
the study drug.
Patients
Eligible patients were at least 50 years of age and fulfilled the
following major criteria with reference to the study eye: best-
corrected visual acuity (BCVA) of 24 letters or better using
Early Treatment Diabetic Retinopathy Study charts (20/320
Snellen equivalent), diagnosis of GA secondary to AMD confirmed
using fundus autofluorescence imaging with GA area size of 2.5
mm2 or more and 17.5 mm2 or less, presence of any pattern of
hyperautofluorescence in the junctional zone of GA, and at least 1
focal lesion of 1.25 mm2 or more if GA was multifocal.
Geographic atrophy, exudative AMD, or both were permitted in
the contralateral eye. An independent central reading center (Dig-
ital Angiography Reading Center, Great Neck, NY) confirmed
lesion eligibility. Major exclusion criteria with reference to the
study eye included GA secondary to causes other than AMD,
history or current evidence of exudative AMD, and retinal disease
other than AMD. For a complete list of eligibility criteria, see the
Appendix.
Outcome Measures
The primary efficacy end point was the change from baseline tomonth
12 in the square root of the GA lesion area as assessed using fundus
autofluorescence imaging. Images were assessed by the central
reading center. Applying the square root transformation to GA lesion
areameasurements hasbeen shown to eliminate thedependence ofGA
lesion growth rate on baseline area.25e29 Secondary outcome mea-
sures includedmean change from baseline tomonth 12 for each of the
following: untransformed GA lesion area, distance of GA lesion from
the fovea (foveal encroachment) measured using fundus187
Figure 1. Clinical trial flowchart. Eligible patients were randomized to receive intravitreal sham injections or intravitreal injections of pegcetacoplan
monthly or every other month (EOM) for 12 months. Patients returned at months 15 and 18 for safety and efficacy follow-up, with the exception of an
additional 5, 7, and 8 patients in the sham, pegcetacoplan monthly, and pegcetacoplan EOM groups, respectively. A modified intention-to-treat (mITT)
population was used for the efficacy analysis and was defined as all patients who received at least 1 injection and underwent at least 1 follow-up examination
at month 2 or later at which primary efficacy data were collected. *n ¼ 80 patients in the analysis of geography atrophy change because of missing evaluable
data after baseline for 1 patient.
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BCVA), and low-luminance visual acuity deficit (LL-VD). Low-
luminance visual acuity deficit was derived by subtracting LL-
BCVA from BCVA. The primary safety end point was the fre-
quency and severity of treatment-emergent adverse events.
Genetic Analysis
Blood samples were collected for genetic marker analysis and geno-
typed on the Axiom Precision Medicine Chip (Thermo Fisher Sci-
entific,Waltham,MA). Variants were called with theAxiomAnalysis
Suite using the Best Practice Workflow (see Appendix for details).
Statistical Analysis
A sample size of 240 patients (pegcetacoplan monthly, n ¼ 80;
pegcetacoplan EOM, n ¼ 80; sham monthly, n ¼ 40; and sham188EOM, n ¼ 40) was calculated to provide approximately 90% po-
wer to detect a 30% reduction in annual square root area increase of
square root GA area for the pegcetacoplan-treated groups
compared with the pooled sham group. Calculations assumed
average square root GA area change of 0.33 mm/year without
treatment, standard deviation of annual square root area change of
0.2 mm/year,25,29 and a 15% to 20% loss to follow-up by month 12
and were based on 2-sided t tests at the a ¼ 0.1 level.
All efficacy analyses were performed on the modified intention-
to-treat population, defined as all patients who received at least 1
injection and had undergone at least 1 examination at month 2 or
later at which primary efficacy data were collected (Fig 1). The
sham groups were pooled for all analyses. Changes from
baseline in the square root GA lesion area measurements at
months 2, 6, 12, and 18 were estimated with a linear mixed-
effects model for repeated measures using observed data. The
linear mixed-effect model included treatment and visit as factors





Monthly (n [ 86) Pegcetacoplan Every Other Month (n [ 79)
Patient demographics
Age (yrs), mean (SD) 78.4 (7.43) 79.6 (7.51) 80.9 (7.55)
Female gender, no. (%) 49 (60.5) 55 (64.0) 50 (63.3)
White race, no. (%) 81 (100.0) 84 (97.7) 76 (96.2)
Study characteristics
Total area of GA (mm2), mean (SD) 8.2 (4.05) 8.0 (3.85) 9.0 (4.47)
Square root area of GA (mm), mean (SD) 2.8 (0.72) 2.7 (0.67) 2.9 (0.77)
Bilateral GA, no. (%) 72 (88.9) 71 (82.6) 64 (81.0)
CNV in the fellow eye, no. (%) 29 (35.8) 36 (41.9) 28 (35.4)
BCVA letter score, mean (SD) 59.8 (17.2) 59.8 (15.7) 58.4 (16.0)
20/200 or worse 12 (14.8) 9 (10.5) 10 (12.7)
20/160e20/50 33 (40.7) 50 (58.1) 44 (55.7)
20/40 or better 36 (44.4) 27 (31.4) 25 (31.6)
Snellen equivalent (median) 20/50 20/63 20/63
LL-BCVA letter score, mean (SD) 33.6 (17.8) 36.3 (16.6) 31.4 (17.1)
Snellen equivalent (median) 20/200 20/200 20/250
LL-VD letter score, mean (SD) 26.2 (17.1) 23.5 (14.5) 27.1 (15.7)
BCVA ¼ best-corrected visual acuity; CNV ¼ choroidal neovascularization; GA ¼ geographic atrophy; LL-BCVA ¼ low-luminance best-corrected visual
acuity; LL-VD ¼ low-luminance visual acuity deficit, which is derived by subtracting LL-BCVA from BCVA; SD ¼ standard deviation.
Figure 2. Graph showing the change from baseline in square root
geographic atrophy (GA) area measurements in the study eye. Least squares
(LS) means and their standard errors (SEs) were estimated from a mixed-
effect model that included treatment and visit as factors and baseline
geographic atrophy (GA) lesion as a covariate, as well as the interaction
term of treatment  visit and visit  baseline. The P values versus the
sham-pooled arm for pegcetacoplan monthly and every other month
(EOM) treatment, respectively, were 0.010 and 0.061 at month 12 and
0.044 and 0.097 at month 18. There was no statistically significant dif-
ference in GA lesion growth between pegcetacoplan monthly and EOM.
Liao et al  Pegcetacoplan for GAand baseline GA lesion as a covariate, as well as the interaction
term of treatment by visit and visit by baseline. Changes in GA
lesion area, foveal encroachment, BCVA, LL-BCVA, and LL-VD
were estimated using the same approach. All statistical tests were 2
sided at the 0.1 level of significance. There were no adjustments for
multiple comparisons. Safety data were collected for all random-
ized patients who received at least 1 injection and were analyzed
using observed data without imputation. All statistical analyses




Between September 24, 2015, and July 22, 2016, 246 patients were
randomized, of whom 243 met the prespecified criteria for analysis
(Fig 1). The pegcetacoplan and sham groups were comparable with
regard to baseline demographic and ocular characteristics (Table 1)
and exhibited a genotype profile typical of patients with GA
secondary to AMD (Table S1, available at www.aaojournal.org).
A total of 218 of 246 patients (88.6%) completed the first 12
months of the study, during which patients in the monthly
pegcetacoplan and monthly sham groups received an average of
10.5 and 11.6 injections, respectively (of 13 possible), and
patients in the EOM pegcetacoplan and EOM sham groups
received an average of 6.2 and 6.6 injections, respectively (of 7
possible). Figure S1 (available at www.aaojournal.org) shows the
percentage of patients in each group who continued treatment or
remained in the study over time. The mean and median number
of injections received by patients in each group over the 12-
month treatment period is presented in Table S2 (available at
www.aaojournal.org).
Efficacy
The study met its primary efficacy end point in both the pegceta-
coplan monthly and EOM groups. The least squares mean change
from baseline to month 12 in square root GA area was 0.25 mm inthe pegcetacoplan monthly group, 0.28 mm in the pegcetacoplan
EOM group, and 0.35 mm in the pooled sham group. Thus, pa-
tients treated with pegcetacoplan monthly had 29% smaller in-
creases (95% confidence interval [CI], 9%e49%; P ¼ 0.008) and
patients treated with pegcetacoplan EOM had 20% smaller in-
creases (95% CI, 0%e40%; P ¼ 0.067) in square root GA lesion
area growth compared with sham, respectively, meeting the pre-
specified significance level (P < 0.1). The primary efficacy results,
including outcomes at month 18, are presented in Figure 2. The
robustness of the primary efficacy results was supported by
multiple sensitivity analyses (Table S3A, available at
www.aaojournal.org). Pegcetacoplan led to 30% and 20%
reductions in untransformed GA lesion area growth at month 12
in the monthly and EOM treatment groups, respectively,189
Ophthalmology Volume 127, Number 2, February 2020consistent with the primary efficacy analysis (Fig S2, available at
www.aaojournal.org).
The effect of pegcetacoplan on GA lesion growth was evident
primarily between months 6 and 12. In a post hoc analysis, re-
ductions in growth rate of square root GA lesion area of 45% (95%
CI, 21e69; P < 0.001) and 33% (95% CI, 9e58; P ¼ 0.009)
compared with sham were observed in the pegcetacoplan monthly
and pegcetacoplan EOM groups, respectively, during months 6 to
12 (Fig 3). Similar reductions in growth rate of untransformed GA
lesion area during the second 6 months were observed (Fig S2).
The influence of 47 prespecified genetic variants associated
with AMD risk, including variants in CFH, CFI, C2/CFB, and
C3,12,13 on GA growth rate and response to pegcetacoplan was
investigated. None of them significantly influenced treatment effect
of pegcetacoplan, indicating that pegcetacoplan’s ability to slow
GA lesion growth is independent of these factors (Table S4,
available at www.aaojournal.org). Two genetic factors,
rs2230199 in C3 and rs3750846 in ARMS2, both previously
shown to influence GA growth, correlated with GA growth rate
in this study independently of treatment assignment (Table S5,
available at www.aaojournal.org).30
The effect of pegcetacoplan on GA lesion growth declined on
cessation of treatment, confirming that the reduced growth rate
during treatment was attributable to pegcetacoplan. The observed
mean changes from months 12 to 18 in the 3 groups were com-
parable (Fig 3). Pegcetacoplan had no effect on changes in foveal
encroachment, visual acuity measures, or LL-VD at month 12
compared with sham treatment. All groups exhibited a gradual
decline in visual acuity measures and LL-VD, with no significant
difference between groups (Fig 4AeC).
Safety
Adverse events are summarized in Table 2. Injection-related cul-
ture-positive endophthalmitis occurred in 2 pegcetacoplan-treatedFigure 3. Bar graph showing post hoc exploratory analyses: growth in geograph
period. Means and standard errors (SEs) of patients who had values at both vis
pegcetacoplan arm versus the sham-pooled arm based on a 1-way analysis of varia
significant difference for months 0 to 6 and months 12 to 18 and showed a *P
pegcetacoplan every other month (EOM) for the lesion growth from months 6
190eyes. Both patients withdrew from the study. Culture-negative
endophthalmitis occurred in 1 pegcetacoplan-treated eye. The pa-
tient resumed pegcetacoplan treatment after missing 1 dose.
There was a higher incidence of adverse events reported as
choroidal neovascularization (CNV) or neovascular AMD in study
eyes treated with pegcetacoplan (18/86 eyes [20.9%; 95% CI,
12.9e31.0] and 7/79 eyes [8.9%; 95% CI, 3.6e17.4] in the
monthly and EOM groups, respectively) than in sham-treated eyes
(1/81 eyes [1.2%]; 95% CI, 0e6.7), as shown in Table 2.
Fluorescein angiography (FA) was performed at the discretion of
the investigator in a subset of the eyes in which this event
occurred. In the monthly group, FA imaging was acquired in 10
eyes and evidence of CNV was confirmed in 5 of these eyes. In
the EOM group, FA was acquired in 7 eyes and CNV was
confirmed in 5 of these eyes. Fluorescein angiography was not
acquired in the patients in the sham group. All 10 cases of CNV
confirmed by FA were classified as occult CNV by the reading
center. Because the presence of CNV was not confirmed by
either FA or OCT angiography in most cases, these events are
referred to herein as exudative AMD. Exudative AMD was
identified more frequently with monthly pegcetacoplan dosing
and was more common in patients with a history of CNV in the
contralateral eye (Table 2). Development of exudative AMD was
not associated with any substantial change in visual acuity
(Table S6, available at www.aaojournal.org). Patients who
demonstrated exudative AMD showed no change in mean
BCVA at the time of diagnosis compared with the visit before
diagnosis. Mean BCVA at month 18 in these patients was 54
letters and was similar to that of patients who did not
demonstrate this event (53 letters). There was no discernible
temporal clustering of onset of exudative AMD, although most
(20/26) instances were observed during the treatment period.
Reading center assessment of OCT imaging performed at the
time of the investigator-determined onset of exudative AMD
revealed the following: 14 of 26 eyes showed subretinal fluid,ic atrophy (GA) lesion size (in millimeters) in the study eye per 6-month
its in each summary period are shown. Pairwise comparisons for either the
nce using the least significant difference method for multiplicity showed no
value of 0.0004 for pegcetacoplan monthly and a **P value of 0.009 for
to 12.
Figure 4. Graphs showing the change from baseline in visual acuity. A, Best-corrected visual acuity (BCVA) assessed with the Early Treatment Diabetic
Retinopathy Study chart. B, Low-luminance BCVA (LL-BCVA). C, Low-luminance visual acuity deficit (LL-VD), which is derived by subtracting LL-
BCVA from BCVA. Least-squares (LS) means and standard errors (SEs) were estimated from a mixed-effect model that included treatment and visit as
factors and baseline value of the end point as a covariate, as well as the interaction term of treatment  visit and baseline  visit. EOM ¼ every other
month.
Liao et al  Pegcetacoplan for GAsubretinal hyperreflective material, or both along with intraretinal
cystic changes; 5 of 26 eyes showed cystic changes only; and 7 of
26 patients showed no exudative changes on OCT.
Patients who demonstrated study eye exudative AMD during
the treatment period discontinued study treatment. All but 2 pa-
tients demonstrating exudative AMD were treated with VEGF in-
hibitors. Nineteen of the 26 patients remained in the study through
month 18, and available data from these patients were included in
the efficacy and safety analyses. We repeated the primary analysis
excluding data from patients who demonstrated study eye exuda-
tive AMD to evaluate the impact of these data on the results. The
results were consistent with those observed in the modified
intention-to-treat population (Table S3B, available at
www.aaojournal.org). Of note, during the 12-month treatment
period, only 3 patients in the monthly pegcetacoplan-treated group
and no patients in the other groups demonstrated exudative AMD
in the contralateral eye. There were no reports of new-onset
exudative AMD in the contralateral eye during the follow-up
period.
Pegcetacoplan administration had no long-term effect on
intraocular pressure, as assessed by preinjection measurements.
Postinjection intraocular pressure was assessed within 15 minutes
of pegcetacoplan injection, and elevations of more than 30 mmHg
resolved spontaneously or with standard intraocular pressure-
lowering procedures that included, but were not limited to,
ocular massage, intraocular pressure-reducing medications, anterior
paracentesis, or a combination thereof before patients
returned home.The incidences of treatment-emergent adverse events (TEAEs)
in the study eye and of nonocular TEAEs are summarized in
Table S7A and B (available at www.aaojournal.org). Nonocular
TEAEs generally were typical of the elderly study population,
and their incidences were similar between the pegcetacoplan and
sham groups. There were 8 deaths (2 in the pegcetacoplan
monthly group, 2 in the pegcetacoplan EOM group, and 4 in the
sham group). No nonocular TEAEs or deaths were considered
related to pegcetacoplan treatment. Hematologic analysis,
urinalysis, clinical chemistry tests, and serum complement profile
assays (CH50, C3 level) did not identify any patterns related to
pegcetacoplan.
Discussion
The Filly study of pegcetacoplan as a therapy for GA sec-
ondary to AMD met its primary end point by reducing GA
lesion growth rate by 29% and 20% compared with sham
treatment in patients receiving pegcetacoplan monthly or
EOM, respectively, over 12 months. The effect was partic-
ularly notable during the second 6 months of treatment, with
observed reductions of 45% and 33% for pegcetacoplan
monthly and EOM, respectively. The growth rate of GA
lesions in the sham group was consistent with that observed
in other studies of GA.22 The ability of pegcetacoplan to
reduce GA lesion growth rate markedly also was evident191









Month (n [ 79)
Adverse events, no. of patients (%)
SAEs in the study eye 1 (1.2) 4 (4.7) 2 (2.5)
SAEs in the contralateral eye 1 (1.2)* 0 0
Systemic (nonocular) SAEs 23 (28.4) 19 (22.1) 24 (30.4)
TEAEs in the study eye 47 (58.0) 65 (75.6) 49 (62.0)
TEAEs in the contralateral eye 36 (44.4) 31 (36.0) 18 (22.8)
Systemic (nonocular) TEAEs 64 (79.0) 69 (80.2) 58 (73.4)
Treatment-related AEs in the study eye 0 22 (25.6) 11 (13.9)
Systemic (nonocular) treatment related AEs 0 0 0
Ocular SAEs in the study eye, no. of patients (%), no. of events
Endophthalmitisy 0 2 (2.3), 2 1 (1.3), 1
Intraocular pressure increased 0 1 (1.2), 2 1 (1.3), 1
Retinal detachment 0 1 (1.2), 1 0
Dry AMD 1 (1.2), 1 0 0
Incidence of exudation in the study eye during study (as determined by the investigator)
Patients with exudation in the study eye (%) 1 (1.2) 18 (20.9) 7 (8.9)
95% exact CI for incidence 0.0%e6.7% 12.9%e31.0% 3.6%e17.4%
With history of CNV in contralateral eye, no. of patients 29 36 28
Patients with exudation in the study eye (%) 0 12 (33.3) 5 (17.9)
95% exact CI for incidence 0.0%e11.9% 18.6%e51.0% 6.1%e36.9%
No CNV history in contralateral eye, no. of patients 52 50 51
Patients with exudation in the study eye (%) 1 (1.9) 6 (12.0)z 2 (3.9)
95% exact CI for incidence 0.0%e10.3% 4.5%e24.3% 0.5%e13.5%
AE ¼ adverse event; AMD ¼ age-related macular degeneration; CI ¼ confidence interval; CNV ¼ choroidal neovascularization; SAE ¼ serious adverse
event; TEAE ¼ treatment emergent adverse event.
*Case of facial bone fracture.
yTwo culture-positive results for coagulase-negative Staphylococcus.
zOne culture-negative result in the monthly group.
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contralateral eyes in patients with bilateral GA and followed
a similar time course. Treatment benefit from pegcetacoplan
was independent of genetic risk factors historically associ-
ated with AMD tested in the study. The treatment effect was
maintained over the 18-month study. However, GA growth
rate in pegcetacoplan-treated eyes began increasing after
cessation of treatment at 12 months, suggesting a need for
continuous therapy.
The safety profile was similar to that observed in studies
of other intravitreally administered drugs22,31e33 with the
exception of the development of exudative AMD. Two
cases of culture-positive endophthalmitis, a known potential
complication of intravitreal injections, occurred in eyes
treated with pegcetacoplan. This risk may be mitigated in
the future through the use of a liquid pegcetacoplan
formulation that does not require reconstitution. Rates of
nonocular TEAEs in the pegcetacoplan-treated and sham
groups did not differ significantly, and none was attributed
to pegcetacoplan. A higher incidence of exudative AMD
was observed in eyes treated with pegcetacoplan compared
with sham treatment, occurring primarily in patients with a
history of contralateral eye CNV, and was managed with
anti-VEGF drugs. The historical incidence of contralateral-
eye CNV in patients with unilateral exudative AMD
ranges from 6% to 12% per year in various studies, similar
to the incidence of exudative AMD among patients with192contralateral-eye CNV who received pegcetacoplan
EOM.34,35 However, the difference in incidence of new-
onset exudative AMD between pegcetacoplan-treated eyes
and sham-treated eyes, with the appearance of a dose
response, suggests that pegcetacoplan altered the
course of AMD.
Complement activation via all 3 activation pathways
leads to cleavage of complement C3 into C3a and C3b,
followed by convertase formation, C5 activation, and for-
mation of the membrane attack complex. A number of
compounds that target various components of the comple-
ment system have been tested in clinical trials in GA. In-
hibition downstream of C3 at the level of C5, or inhibition
of factor D, a key alternative pathway component, failed to
reduce GA lesion growth compared with sham treat-
ment,22,25 raising the question of why C3 inhibition would
be effective when other strategies targeting complement
were not. We hypothesize that one mechanism by which
complement activation is pathogenic in GA is related to an
imbalance in deposition and removal of C3 fragments on the
retinal pigment epithelium, photoreceptors, capillary endo-
thelial cell surfaces, or a combination thereof, resulting in
C3 fragment accumulation, which promotes phagocytosis
by microglia or macrophages. Observations in other patho-
logic settings support this hypothesis. The accumulation of
C3b and its fragments (iC3b, C3dg, C3d) on mammalian
cell surface has been demonstrated to promote phagocytosis
Liao et al  Pegcetacoplan for GAby macrophages and microglia.36e38 In addition, activated
macrophages and microglia are associated with retinal
degeneration in several experimental and clinical conditions,
including AMD.23,39e41 We hypothesize that oxidative
stress-mediated reduction in endocytosis may contribute to
the accumulation of C3 fragments at the surface of cells
affected in GA. Consistent with this hypothesis, in vitro
studies have demonstrated that retinal pigment epithelium
cells can use endocytosis as a strategy to prevent accumu-
lation of complement components at the cell surface.42 By
inhibiting C3 activation, pegcetacoplan would prevent
further C3 deposition, allowing cells to avoid
phagocytosis and to survive. In the absence of ongoing
phagocytic attack, viable endothelium in the
choriocapillaris adjacent to areas of GA may regrow new
vessels. Because these vessels would lack the barrier
functions of mature endothelium, they may have increased
propensity to leak, which may explain the higher
incidence of exudative AMD observed in pegcetacoplan-
treated eyes relative to sham.
C3 inhibition may have additional effects on the activity
of microglia and macrophages. These cells have been
classified broadly into 3 categories: (1) resting M0; (2)
proinflammatory, prophagocytic M1; and (3) reparative,
proangiogenic M2 phenotypes, but exhibit high phenotypic
plasticity in response to changes in their local microenvi-
ronment.43,44 An analysis of macrophage polarization in
postmortem eyes of patients with or without AMD showed
that there is a tendency toward greater M1 activity in GA
and more M2 activity in exudative AMD.39 Several lines of
evidence suggest that the C5 activation product C5a can
polarize macrophages toward an M1 phenotype and that
lack of complement results in a shift toward M2.45,46 We
hypothesize that complement inhibition with pegcetacoplan,
by blocking the activation of C3 and preventing formation
of downstream effectors such as C5a, may permit M1
macrophages and microglia to transition to a proangiogenic,
reparative M2 phenotype in the setting of GA, before
reverting to a resting M0 stage.44
This study had limitations. The functional outcomes
assessed measure central vision, which can remain rela-
tively well preserved for a time in patients with GA,
despite functional loss in extrafoveal regions of the retina
and progression of atrophy that ultimately will lead to
severe central vision deficits. Measures of central vision
do not reflect the full spectrum of impairments experi-
enced by patients with GA, and this limited the ability to
detect functional benefit. Alternative functional assess-
ments such as reading speed and evaluation of retinal
function by microperimetry may be better indicators of
retinal function and health. Another limitation was that
patients who demonstrated study eye exudative AMD
discontinued treatment, so it was not possible to investi-
gate the ability of ongoing pegcetacoplan therapy to
reduce GA lesion growth further in this population. These
limitations will be addressed in phase 3 studies, in which
additional functional outcome measures will be assessed
and patients who demonstrate exudative AMD will
continue study treatment in addition to receiving VEGF
inhibitor therapy.In conclusion, this is the first study that demonstrated that
C3 inhibition can slow the progression of GA. Treatment
with pegcetacoplan was associated with significant re-
ductions in GA lesion growth during 12 months of therapy,
particularly during the latter 6 months, and demonstrated
acceptable safety to proceed to phase 3 studies. These
studies will define the efficacy and safety profile of pegce-
tacoplan further as a treatment for patients with GA, a
blinding disease with no approved therapies.References
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